EMA Authorised: Alkindi (hydrocortisone) — Immedica Pharma AB

View source ↗

Summary

EMA authorises Alkindi (hydrocortisone) for adrenal insufficiency, expanding treatment options.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenal Insufficiency

Drugs mentioned

• Alkindi (hydrocortisone)

Snippet

Status: Authorised. Therapeutic area: Adrenal Insufficiency. MAH: Immedica Pharma AB. Decision date: 12/06/2026